MCID: MNC007
MIFTS: 58

Monocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 55 15 73
M5b Acute Differentiated Monocytic Leukemia 73
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD10 33 C93
ICD9CM 35 206.8

Summaries for Monocytic Leukemia

Disease Ontology : 12 A myeloid leukemia that is characterized by a dominance of monocytes in the marrow.

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to leukemia, acute monocytic and acute monoblastic leukemia. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Busulfan and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Wikipedia : 76 Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the... more...

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 33.8 CD14 KAT6A KIAA0100 KMT2A
2 acute monoblastic leukemia 32.4 CSF2 CXCL8 IL6 KMT2A
3 langerhans cell histiocytosis 29.9 CSF1 CSF2 IFNG
4 hematopoietic stem cell transplantation 29.6 IFNG IL6 TNF
5 respiratory failure 29.5 CXCL8 F3 TNF
6 thrombocytosis 29.5 CSF2 F3 IL6
7 endocarditis 29.4 CXCL8 IL6 TNF
8 obstructive jaundice 29.4 CXCL8 IL6 TNF
9 graft-versus-host disease 29.4 IFNG IL1B IL6 TNF
10 cytomegalovirus infection 29.2 CASP3 CXCL8 IL1B IL6 TNF
11 aplastic anemia 29.2 CSF1 CSF2 IFNG IL6 TNF
12 myeloma, multiple 29.1 CASP3 CSF2 CXCL8 IL6 TNF
13 myelodysplastic syndrome 29.1 CSF1 CSF2 ITGAM KMT2A TNF
14 leukemia, acute myeloid 29.1 CASP3 CSF2 ITGAM JUN KAT6A KMT2A
15 pertussis 29.0 IL1B IL6 ITGAM JUN TNF
16 adult acute monocytic leukemia 12.6
17 aleukemic monocytic leukemia cutis 12.4
18 chronic monocytic leukemia 12.4
19 subacute monocytic leukemia 12.4
20 leukemia 11.0
21 fixed drug eruption 10.3 CASP3 IFNG
22 b-cell growth factor 10.3 IFNG IL6
23 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
24 critical limb ischemia 10.2 IL6 TNF
25 juvenile ankylosing spondylitis 10.2 IL6 TNF
26 leukomalacia 10.2 IL6 TNF
27 scorpion envenomation 10.2 IL6 TNF
28 cardiogenic shock 10.2 IL6 TNF
29 periodontitis, chronic 10.2 IL1B IL6
30 paraneoplastic syndromes 10.2 IL1B IL6
31 large granular lymphocyte leukemia 10.2 CSF2 IFNG
32 retinitis pigmentosa 73 10.2 F3 IL1B
33 spinal cord injury 10.1 CASP3 IL6 TNF
34 gastrointestinal system cancer 10.1 CASP3 IL6 TNF
35 atherosclerosis susceptibility 10.1 IL6 PPARG TNF
36 overnutrition 10.1 IL6 PPARG TNF
37 filariasis 10.1 IFNG IL6 TNF
38 spondyloarthropathy 10.1 IFNG IL6 TNF
39 chronic mucocutaneous candidiasis 10.1 IFNG IL6 TNF
40 autoimmune myocarditis 10.1 IFNG PPARG TNF
41 mycobacterium chelonae 10.1 CD14 CXCL8
42 mycobacterium kansasii 10.1 CD14 CXCL8
43 acute transverse myelitis 10.1 CXCL8 IL6
44 salmonellosis 10.1 IFNG IL1B JUN
45 cerebral palsy 10.1 IL1B IL6 TNF
46 lyme disease 10.1 IL1B IL6 TNF
47 juvenile rheumatoid arthritis 10.1 IL1B IL6 TNF
48 chronic fatigue syndrome 10.1 IL1B IL6 TNF
49 intermediate uveitis 10.1 IFNG IL6 TNF
50 rheumatic disease 10.1 IFNG IL1B TNF

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 CASP3 CD14 CSF1 CSF2 F3 IFNG
2 cardiovascular system MP:0005385 10.37 CASP3 CSF1 CSF2 F3 IFNG IL1B
3 homeostasis/metabolism MP:0005376 10.37 CASP3 CD14 CSF1 CSF2 F3 IFNG
4 cellular MP:0005384 10.36 CASP3 CSF1 CSF2 F3 IFNG IL6
5 growth/size/body region MP:0005378 10.36 CASP3 CD14 CSF1 CSF2 F3 IFNG
6 immune system MP:0005387 10.36 CASP3 CD14 CSF1 CSF2 F3 IFNG
7 behavior/neurological MP:0005386 10.34 CASP3 CSF1 CSF2 F3 IFNG IL6
8 integument MP:0010771 10.27 CASP3 CSF1 CSF2 F3 IFNG IL1B
9 mortality/aging MP:0010768 10.27 CASP3 CD14 CSF1 CSF2 F3 IFNG
10 endocrine/exocrine gland MP:0005379 10.21 CASP3 CSF1 CSF2 IFNG IL6 JUN
11 craniofacial MP:0005382 10.18 CASP3 CSF1 CSF2 IFNG IL1B KAT6A
12 nervous system MP:0003631 10.18 CASP3 CSF1 CSF2 F3 IFNG IL1B
13 embryo MP:0005380 10.17 CSF2 F3 IFNG JUN KAT6A KMT2A
14 liver/biliary system MP:0005370 10.08 CSF1 IFNG IL6 JUN KAT6A KMT2A
15 muscle MP:0005369 10.03 CASP3 CSF1 F3 IFNG IL6 KMT2A
16 neoplasm MP:0002006 10.01 CSF2 F3 IFNG IL1B IL6 KMT2A
17 reproductive system MP:0005389 9.91 CASP3 CSF1 CSF2 IFNG IL6 KAT6A
18 no phenotypic analysis MP:0003012 9.87 CASP3 CSF1 IFNG JUN KMT2A PPARG
19 respiratory system MP:0005388 9.81 CASP3 CD14 CSF1 CSF2 F3 IFNG
20 skeleton MP:0005390 9.73 CASP3 CD14 CSF1 CSF2 IFNG IL1B
21 vision/eye MP:0005391 9.23 CASP3 CSF1 F3 IFNG IL6 JUN

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
2
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
3
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
4
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
6
Mesna Approved, Investigational Phase 3 3375-50-6 598
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
10
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
11
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
12
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
14
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
15
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
16
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
17
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
18
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
23
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
24
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
25
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
26
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
27
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
28
Carmustine Approved, Investigational Phase 3 154-93-8 2578
29
Hydroxyurea Approved Phase 3 127-07-1 3657
30
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
31
Midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
32
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
33
Cyproheptadine Approved Phase 3 129-03-3 2913
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
36
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
37 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
38 Vaccines Phase 3,Phase 1
39 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Gemtuzumab Phase 2, Phase 3,Phase 3,Phase 1
41 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Etoposide phosphate Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Alkylating Agents Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antirheumatic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
6 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
9 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
10 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
12 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
13 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
14 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
15 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
16 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
17 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
18 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
19 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
20 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
21 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
22 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
23 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
24 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
25 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
26 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
27 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
28 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
29 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
30 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
31 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
33 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
34 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
35 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Unknown status NCT00509093 Phase 2 imatinib mesylate
36 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
37 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
38 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
39 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
40 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
41 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
42 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
44 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
46 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
47 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
48 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

41
Monocytes, Myeloid, Bone, Bone Marrow, T Cells, Skin, Lung

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 545)
# Title Authors Year
1
Cellular internalization and antioxidant activity of cerium oxide nanoparticles in human monocytic leukemia cells. ( 29593393 )
2018
2
Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. ( 29967760 )
2018
3
Anti-Cancerous Effect of Inonotus taiwanensis Polysaccharide Extract on Human Acute Monocytic Leukemia Cells through ROS-Independent Intrinsic Mitochondrial Pathway. ( 29382173 )
2018
4
Suppressive effects of metformin on T-helper 1-related chemokines expression in the human monocytic leukemia cell line THP-1. ( 29630425 )
2018
5
Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report. ( 29755835 )
2018
6
Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells. ( 29435054 )
2018
7
Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. ( 29843647 )
2018
8
Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining. ( 29721252 )
2018
9
Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3. ( 30074149 )
2018
10
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
11
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
12
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
13
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
14
C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia. ( 28693135 )
2017
15
The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-I_B Signaling. ( 28832545 )
2017
16
5-Aminoimidazole-4-carboxamide ribonucleoside-induced autophagy flux during differentiation of monocytic leukemia cells. ( 28975042 )
2017
17
Treatment-related acute granulocyte-monocytic leukemia from multiple myeloma: A case report and literature review. ( 29390389 )
2017
18
Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. ( 29156705 )
2017
19
5a89azaa892'a89deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2a89CCR2a89ERK signaling pathway. ( 28627644 )
2017
20
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. ( 27859216 )
2017
21
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
22
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
23
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
24
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
25
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
26
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
27
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
28
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
29
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
30
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
31
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
32
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
33
A Wnt pathway activator induces apoptosis and cell death in mouse monocytic leukemia cells. ( 27623760 )
2016
34
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
35
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
36
Antioxidation and antiproliferation of ethanol extracts from edible mushrooms against U937 human monocytic leukemia cells. ( 27976050 )
2016
37
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
38
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2016
39
Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells. ( 26134921 )
2015
40
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
41
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
42
Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. ( 26582014 )
2015
43
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
44
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
45
Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. ( 25546124 )
2015
46
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
47
Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplant in patients with chronic myelo-monocytic leukemia (CMML) ? ( 26576835 )
2015
48
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
49
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
50
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
2
Show member pathways
13.93 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
3
Show member pathways
13.76 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
4
Show member pathways
13.49 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
5
Show member pathways
13.46 CASP3 CSF1 CSF2 CXCL8 IFNG IL1B
6
Show member pathways
13.4 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
7
Show member pathways
13.15 CASP3 CSF2 CXCL8 IL1B IL6 JUN
8
Show member pathways
13.11 CD14 CXCL8 IFNG IL1B IL6 JUN
9
Show member pathways
12.96 CASP3 CXCL8 IFNG IL1B IL6 TNF
10
Show member pathways
12.96 CASP3 CD14 CSF2 ITGAM JUN PPARG
11 12.93 CASP3 CXCL8 IFNG IL6 JUN PPARG
12
Show member pathways
12.91 CASP3 CXCL8 IFNG IL1B IL6 JUN
13 12.87 CASP3 CD14 CSF1 IL1B JUN TNF
14
Show member pathways
12.87 CD14 CXCL8 IFNG IL1B IL6 TNF
15
Show member pathways
12.76 CASP3 IFNG IL1B JUN TNF
16
Show member pathways
12.69 CASP3 CD14 IL1B JUN TNF
17
Show member pathways
12.68 IFNG IL1B IL6 JUN TNF
18
Show member pathways
12.68 CD14 IFNG IL1B IL6 TNF
19
Show member pathways
12.61 CASP3 CSF2 IFNG JUN TNF
20
Show member pathways
12.56 CSF2 IFNG IL1B IL6 JUN TNF
21 12.48 CSF2 IL6 JUN TNF
22
Show member pathways
12.47 CD14 CXCL8 IFNG IL1B IL6 JUN
23
Show member pathways
12.47 CASP3 CSF2 CXCL8 IFNG IL1B IL6
24
Show member pathways
12.45 CSF1 IFNG IL1B IL6 TNF
25
Show member pathways
12.41 CASP3 IFNG IL1B ITGAM JUN TNF
26 12.4 CD14 CSF2 CXCL8 IL6 ITGAM KMT2A
28
Show member pathways
12.38 CD14 CXCL8 IL6 JUN TNF
29 12.38 CASP3 CD14 IFNG IL1B IL6 ITGAM
30 12.37 CASP3 IL6 JUN TNF
31
Show member pathways
12.37 CXCL8 F3 IL1B IL6 JUN TNF
32
Show member pathways
12.35 CXCL8 IFNG IL1B IL6 TNF
33
Show member pathways
12.34 CD14 CXCL8 IFNG IL1B IL6 JUN
34 12.33 CASP3 CXCL8 IL1B IL6 JUN TNF
35
Show member pathways
12.29 IL1B IL6 JUN TNF
36
Show member pathways
12.27 CXCL8 IL1B ITGAM JUN MYH7B
37 12.27 CASP3 IFNG IL6 TNF
38 12.22 CSF1 IFNG IL1B JUN PPARG TNF
39
Show member pathways
12.2 IFNG IL1B IL6 JUN TNF
40
Show member pathways
12.2 CD14 CSF2 IFNG IL1B IL6 ITGAM
41 12.19 IFNG IL1B JUN TNF
42 12.17 CASP3 CXCL8 IFNG IL1B IL6 TNF
43
Show member pathways
12.16 CXCL8 IFNG IL1B IL6 JUN
44 12.16 CD14 CSF1 CSF2 IFNG IL6 ITGAM
45 12.13 CXCL8 IL1B IL6 ITGAM TNF
46 12.1 CXCL8 IFNG IL1B IL6 JUN KMT2A
47 12.1 CASP3 CSF1 CSF2 IL1B IL6 JUN
48 12.03 CASP3 CXCL8 F3 IL1B IL6 JUN
49 12.01 CD14 CXCL8 IL1B TNF
50 12.01 CD14 CSF1 CSF2 IL1B IL6 ITGAM

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CD14 CSF1 CSF2 CXCL8 F3 IFNG
2 membrane raft GO:0045121 9.56 CASP3 CD14 ITGAM TNF
3 extracellular space GO:0005615 9.32 CD14 CSF1 CSF2 CXCL8 F3 IFNG
4 MOZ/MORF histone acetyltransferase complex GO:0070776 9.16 KAT6A KAT6B

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.96 CASP3 CD14 IL1B JUN
2 negative regulation of transcription, DNA-templated GO:0045892 9.95 CSF2 IFNG JUN KAT6A KAT6B PPARG
3 inflammatory response GO:0006954 9.93 CD14 CSF1 CXCL8 IL1B IL6 TNF
4 response to organic cyclic compound GO:0014070 9.92 CASP3 IL1B JUN PPARG
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 IL1B IL6 PPARG TNF
6 regulation of signaling receptor activity GO:0010469 9.91 CSF1 CSF2 CXCL8 IFNG IL1B IL6
7 response to organic substance GO:0010033 9.88 CASP3 JUN PPARG TNF
8 cellular response to organic cyclic compound GO:0071407 9.87 CASP3 IL1B TNF
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 CSF2 IFNG IL6
10 regulation of insulin secretion GO:0050796 9.87 IFNG IL1B TNF
11 apoptotic signaling pathway GO:0097190 9.86 CASP3 CD14 TNF
12 positive regulation of transcription, DNA-templated GO:0045893 9.86 IL1B IL6 JUN KAT6A KAT6B KMT2A
13 positive regulation of interleukin-6 production GO:0032755 9.85 IL1B IL6 TNF
14 humoral immune response GO:0006959 9.85 IFNG IL6 TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 IL6 JUN TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 CD14 IL1B TNF
17 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 CASP3 F3 PPARG TNF
18 positive regulation of neuron apoptotic process GO:0043525 9.83 CASP3 IL1B JUN
19 positive regulation of interferon-gamma production GO:0032729 9.83 CD14 IL1B TNF
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 IFNG IL1B TNF
21 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.8 CSF2 IL1B TNF
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 CD14 IL1B TNF
23 negative regulation of neurogenesis GO:0050768 9.76 IL1B IL6 TNF
24 positive regulation of osteoclast differentiation GO:0045672 9.74 CSF1 IFNG TNF
25 response to glucocorticoid GO:0051384 9.73 CASP3 IL1B IL6 TNF
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL1B TNF
27 positive regulation of podosome assembly GO:0071803 9.71 CSF2 TNF
28 response to molecule of bacterial origin GO:0002237 9.71 CD14 CXCL8
29 positive regulation of phagocytosis, engulfment GO:0060100 9.71 ITGAM PPARG
30 negative regulation of lipid storage GO:0010888 9.7 IL6 TNF
31 positive regulation of monocyte differentiation GO:0045657 9.7 CSF1 JUN
32 microglial cell activation GO:0001774 9.7 ITGAM JUN TNF
33 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IL1B TNF
34 monocyte differentiation GO:0030224 9.69 CSF2 JUN PPARG
35 regulation of establishment of endothelial barrier GO:1903140 9.68 IL1B TNF
36 positive regulation of fever generation GO:0031622 9.67 IL1B TNF
37 positive regulation of glial cell proliferation GO:0060252 9.67 IL1B IL6 TNF
38 positive regulation of interleukin-23 production GO:0032747 9.66 CSF2 IFNG
39 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG IL1B TNF
40 chronic inflammatory response to antigenic stimulus GO:0002439 9.64 IL1B TNF
41 sequestering of triglyceride GO:0030730 9.64 IL1B TNF
42 positive regulation of vitamin D biosynthetic process GO:0060557 9.6 IFNG TNF
43 positive regulation of neuroinflammatory response GO:0150078 9.5 IL1B IL6 TNF
44 cellular response to lipopolysaccharide GO:0071222 9.43 CD14 CSF2 CXCL8 IL1B IL6 TNF
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.33 IFNG IL1B TNF
46 cytokine-mediated signaling pathway GO:0019221 9.28 CASP3 CSF1 CSF2 CXCL8 F3 IL1B
47 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 IL1B IL6 JUN KAT6A KAT6B KMT2A
48 positive regulation of cell proliferation GO:0008284 10.09 CSF1 CSF2 IFNG IL1B IL6 JUN
49 negative regulation of cell proliferation GO:0008285 10.08 CXCL8 IL1B IL6 JUN PPARG
50 immune response GO:0006955 10.07 CSF2 CXCL8 IFNG IL1B IL6 TNF

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 CASP3 CD14 CSF1 CSF2 CXCL8 F3
2 protease binding GO:0002020 9.5 CASP3 F3 TNF
3 transcription regulatory region DNA binding GO:0044212 9.46 JUN KMT2A PPARG TNF
4 H4 histone acetyltransferase activity GO:0010485 9.26 KAT6A KAT6B
5 cytokine activity GO:0005125 9.17 CSF1 CSF2 CXCL8 IFNG IL1B IL6

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....